`Case 1:24-cv-00053-TSK Document 20-6 Filed 07/03/24 Page 1of2 PagelD #: 2773
`
`EXHIBIT 6
`EXHIBIT 6
`
`
`
`Case 1:24-cv-00053-TSK Document 20-6 Filed 07/03/24 Page 2 of 2 PageID #: 2774
`
`
`
`KATHRYN S. KAYALI
`(202) 434-5644
`kkayali@wc.com
`
`
`
`
`Via Email
`
`June 21, 2024
`
`
`
`John R. Labbe
`MARSHALL, GERSTEIN & BORUN LLP
`233 South Wacker Drive
`6300 Willis Tower
`(312) 474-6300
`jlabbe@marshallip.com
`
`
`Re:
`
`In re Aflibercept Patent Litigation, No. 1:24-md-03103-TSK
`Regeneron Pharms., Inc. v. Amgen Inc., No. 1:24-cv-00039-TSK (N.D.W. Va.)
`
`Counsel:
`
`Regeneron hereby produces documents bearing the following Bates numbers RGN-EYLEA-
`BIOSIM-AMG-00003827 - RGN-EYLEA-BIOSIM-AMG-00012962. This production consists
`of redacted documents provided to Regeneron from Celltrion, Formycon, and Samsung Bioepis
`on June 12, 2024.
`
`
`This production is password protected; the password is
`
`SL$-0DR#6h@swEJIj*5r
`
`
`
`This document production will be made available for download on Williams & Connolly
`LLP’s secure file transfer site. You will receive an email with an invitation to join the site and
`download instructions shortly.
`
`Please note certain of these documents contain Regeneron’s confidential information, and
`have thus been designated CONFIDENTIAL as appropriate pursuant to the Stipulated Protective
`Order in this case.
`
`
`
`
`
`Sincerely,
`
`/s/ Kathryn S. Kayali
`Kathryn S. Kayali
`
`